<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04287803</url>
  </required_header>
  <id_info>
    <org_study_id>20191107100</org_study_id>
    <nct_id>NCT04287803</nct_id>
  </id_info>
  <brief_title>Prehospital Analgesia in Adults Using Inhaled Methoxyflurane : A Feasibility Study</brief_title>
  <official_title>Prehospital Analgesia in Adults Using Inhaled (PAIN) Methoxyflurane : A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ottawa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain is common and can contribute to both psychological and physiological effects if not
      treated. Currently primary care paramedics have limited selections within their pain
      management tool box. This contributes to inadequate pain management. Methoxyflurane is a
      safe, easy and effective choice in prehospital management of pain. The impact of this
      feasibility trial, will hope to inform the larger multi-centred trial and then support the
      implementation of out-of-hospital Canadian National Guidelines for prehospital pain control,
      enabling paramedics to provide rapid, effective prehospital pain relief to patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single-centred prehospital prospective observational feasibility study to
      evaluate the ability to perform a multicentred step wedge design trial. The feasibility
      outcomes will provide evidence for the development of the multicentred study and will capture
      clinical metrics to inform this larger study. A waver of consent will be sought from the
      ethics board with participation consent for paramedics understanding the risk of using a gas
      for analgesia. Patient &gt;= 18 years of age with traumatic pain with a verbal score &gt;= to 4
      will be enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Feasibility study to inform the multicentred prehospital prospective observational step wedge design trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to ethics approval for single site</measure>
    <time_frame>from ethics submission up to 90 days</time_frame>
    <description>Target: ,&lt;= 3 months (90 days) from ethics submission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to readiness to initiate the clinical trial</measure>
    <time_frame>From ethics approval up to 90 days</time_frame>
    <description>Target, &lt;= 3 months (90 days) from ethics approval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of outcome data collected</measure>
    <time_frame>For length of study, up to 100 patients</time_frame>
    <description>Target: 100% of data captured in &gt;90% cases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study protocol compliance by paramedics</measure>
    <time_frame>For length of study, up to 100 patients</time_frame>
    <description>Target, &gt;= 80%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Verbal numeric pain rating score (0-10) initial and recorded every 5 minutes</measure>
    <time_frame>For length of study, up to 100 patients specifically from patient contact to transfer of care in the emergency department</time_frame>
    <description>Degree of change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for rescue medication (as defined by addition of any other pain medication after methoxyflurane administration, during paramedic care)</measure>
    <time_frame>For length of study, up to 100 patients. specifically from patient contact to transfer of care in the emergency department</time_frame>
    <description>If other medication are used to control pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transport time</measure>
    <time_frame>For length of study, up to 100 patients, specifically departure scene to arrival at hospital</time_frame>
    <description>Defined by departure from scene to arrival at hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first administration of methoxyflurane</measure>
    <time_frame>For length of study, up to 100 patients. Specifically time from patient contact to first inhalation of methoxyflurane</time_frame>
    <description>Time from first patient contact to first inhalation of methoxyflurane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs and level of consciousness</measure>
    <time_frame>From patient contact to transfer of care</time_frame>
    <description>Vital signs including (Heart rate, Blood pressure, Respiratory rate, Oxygen saturation, Temperature, Glasgow Coma Scale (GCS))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events post administration of methoxyflurane:</measure>
    <time_frame>For length of study, up to 100 patients. Specifically from patient contact to transfer of care</time_frame>
    <description>Example: any advanced airway interventions, oxygen requirement (oxygen saturations &lt;94%), drop in blood pressure by 40% and/or &lt;90 systolic, complaints of nausea or vomiting, malignant hyperthermia reaction).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pain, Acute</condition>
  <condition>Trauma</condition>
  <arm_group>
    <arm_group_label>intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methoxyflurane will be introduced and data will be captured to inform future multicentred step wedge design study. (This study is a feasibility study)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methoxyflurane</intervention_name>
    <description>Methoxyflurane 3mls will be self administered by patients meeting the inclusion criteria with acute traumatic pain scores &gt;=4</description>
    <arm_group_label>intervention Arm</arm_group_label>
    <other_name>Penthrox</other_name>
    <other_name>Penthrane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;=18 years of age

          -  Acute pain from traumatic injury

          -  numeric pain score &gt;=4

        Exclusion Criteria:

          -  Allergy or sensitivity to methoxyflurane

          -  History or family history of malignant hyperthermia

          -  Pregnant or breast-feeding patients

          -  Known renal impairment

          -  Known liver disease

          -  Methoxyflurane use within previous 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Austin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael A Austin, MD</last_name>
    <phone>613 737-7228</phone>
    <email>maustin@toh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juiie Sinclair</last_name>
    <phone>613-737-7228</phone>
    <email>jusinclair@rppeo.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dr Michael A Austin</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael A Austin, MD</last_name>
      <phone>613-737-7228</phone>
      <email>maustin@toh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Julie SInclair</last_name>
      <phone>63-737-7228</phone>
      <email>jusinclair@rppeo.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prehospital</keyword>
  <keyword>paramedic</keyword>
  <keyword>ambulance</keyword>
  <keyword>methoxyflurane</keyword>
  <keyword>Penthrox</keyword>
  <keyword>Penthrane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methoxyflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>De-identified data for primary and secondary outcome maybe available to share.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

